Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JJ99 | ISIN: US04962H5063 | Ticker-Symbol: YAG2
Tradegate
28.03.24
16:55 Uhr
1,700 Euro
+0,024
+1,43 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ATOSSA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ATOSSA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,6831,73418:17
1,6831,73418:00

Aktuelle News zur ATOSSA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.03.Atossa climbs after cancer therapy update33
19.03.Atossa Therapeutics, Inc.: Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient184SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human...
► Artikel lesen
18.03.Atossa Therapeutics regains compliance with Nasdaq minimum bid price listing requirements10
18.03.Atossa Therapeutics, Inc.: Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements152SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced that on March 15, 2024, the Company received written notice from the...
► Artikel lesen
12.03.Atossa Therapeutics, Inc.: Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors185SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas...
► Artikel lesen
12.03.ATOSSA THERAPEUTICS, INC. - 8-K, Current Report5
22.02.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study339SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet...
► Artikel lesen
12.02.Atossa spikes as H.C. Wainwright starts at Buy on lead asset15
07.02.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial526SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
► Artikel lesen
26.01.Atossa Therapeutics progresses Phase II preventative breast cancer therapy20
09.01.Atossa Therapeutics, Inc.: Atossa Therapeutics Issues Letter to Shareholders238SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
► Artikel lesen
20.11.23Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial25
13.11.23Atossa Therapeutics Inc reports results for the quarter ended in September - Earnings Summary10
13.11.23Atossa Therapeutics GAAP EPS of -$0.05 beats by $0.023
13.11.23ATOSSA THERAPEUTICS, INC. - 10-Q, Quarterly Report6
13.11.23Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update322Achieved significant enrollment milestones in ongoing Phase 2 clinical trialsFour ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS Ended third quarter 2023...
► Artikel lesen
09.11.23Atossa Therapeutics, Inc.: Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors7
09.11.23ATOSSA THERAPEUTICS, INC. - 8-K, Current Report2
06.10.23ATOSSA THERAPEUTICS, INC. - 8-K, Current Report22
18.09.23Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment498SEATTLE, WA / ACCESSWIRE / September 18, 2023 / One in eight women will be diagnosed with breast cancer during their lifetime. However, breast cancer does not affect all women in the same way, and individual...
► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5